Implementing optimal allocation in clinical trials with multiple endpoints
From MaRDI portal
Publication:729721
DOI10.1016/j.jspi.2016.09.002zbMath1394.62157OpenAlexW2531868949WikidataQ40191580 ScholiaQ40191580MaRDI QIDQ729721
Publication date: 22 December 2016
Published in: Journal of Statistical Planning and Inference (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc5435386
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)
Related Items (1)
Sequential monitoring of response-adaptive randomized clinical trials with sample size re-estimation
Cites Work
- Unnamed Item
- Unnamed Item
- Unnamed Item
- Optimal Adaptive Designs for Binary Response Trials
- Optimal biased coins for two-arm clinical trials
- An optimal response-adaptive design with dual constraints
- Sequential monitoring of response-adaptive randomized clinical trials
- A play-the-winner-type urn design with reduced variability
- Multiple analyses in clinical trials. Fundamentals for investigators
- Asymptotic properties of doubly adaptive biased coin designs for multitreatment clinical trials.
- Asymptotically best response-adaptive randomization procedures
- An adaptive randomized design with application to estimation
- Interim analysis of clinical trials based on urn models
- The Randomized Play-the-Winner Rule in Medical Trials
- Group Sequential Tests for Bivariate Response: Interim Analyses of Clinical Trials with Both Efficacy and Safety Endpoints
- Optimality, Variability, Power
- Optimal Response‐Adaptive Designs for Normal Responses
- Implementing Optimal Allocation in Sequential Binary Response Experiments
- The Theory of Response‐Adaptive Randomization in Clinical Trials
- Response‐Adaptive Randomization for Clinical Trials with Continuous Outcomes
- Response-Adaptive Randomization for Survival Trials: The Parametric Approach
- Some aspects of the sequential design of experiments
This page was built for publication: Implementing optimal allocation in clinical trials with multiple endpoints
